Heart failure & cardiomyopathies
Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial
Study context
- Population
- Patients with chronic Chagas cardiomyopathy and reduced EF, ≈100 sites in Latin Americaplanned ≈900
- Planned comparison
- Sacubitril/valsartan vs enalapril, added to standard of care
- Primary endpoint
- Hierarchical composite of:
- Time to CV death
- First heart failure (HF) hospitalization
- Relative change in NT-proBNP from baseline to week 12
Methodological detailsdesign paper, active-controlled, phase IV, multicentre
- Design paper
- Active-controlled
- Phase IV
- Multicentre
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial. JACC Heart Fail. Published August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →